A new phase I clinical trial using anti-PSMA TGF-β-DNR CAR-T cells in prostate cancer was reported with the feasibility and safety of the clinical application of TGF-β-DNR CAR-T cells 155. This evidence concerns the gene FOLH1 and prostate cancer.